Pepgen Inc (PEPG) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Pepgen Inc   (NASDAQ: PEPG)


Pepgen Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Pepgen Inc's ROI in the second quarter of 2026?
Pepgen Inc recorded a cumulative net loss of $-72 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -46.53%.

Within the Healthcare sector 460 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3286 to 3775.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 28.71 % 1.04 % -18.82 % -21.92 % -24.45 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 132 147 161 177 86
Return On Investment (TTM) -46.53 % -54.01 % -67.47 % -74.19 % -80.69 %
PEPG's Overall Ranking # 3775 # 3286 # 2707 # 3644 # 3234
Seq. Investment Change TTM 8.13 % 7.6 % 5.37 % 4.99 % -15.11 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -72 -77 -90 -94 -97

PEPG Company Profile >> Back to PEPG Roi Comparisons >> See Annual PEPG Return On Investment



Return On Investment PEPG's Ranking
Within: No.
Industry # 187
Sector # 461
Overall # 3775

Return On Investment Statistics
High Average Low
-34.24 %
-54.9 %
-80.69 %
(Mar 31 2023)   (Jun 30 2025)



  News about Pepgen Inc Return on Investment ROI

PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 f...

December 16, 2024

Turbulence in Innovation: PepGen Faces Clinical Setback Amidst Competitive Revenue GrowthIn the intricate landscape of biotechnology, where hope for transformative therapies often collides with regulatory challenges, PepGen Inc. (Nasdaq: PEPG) finds itself navigating turbulent waters. The Boston-based clinical-stage company, committed to revolutionizing the treatment of severe neuromuscular and neurological diseases through its next-generation oligonucleotide therapies, recently announced a significant setback. The U.S. Food and Drug Administration (FDA) has issued a clinical hold on its Investigational New Drug (IND) application concerning the CONNECT2-EDO51 Phase 2 study of PGN-EDO51, a promising candidate for treating Duchenne Muscular Dystrophy (DMD).Duchenne Muscular Dystrophy, an incurable and devastating genetic disorder, has long demanded innovation, with patient advocacy groups and medical professionals eagerly anticipating novel treatment options. PGN-EDO51 was positioned as a potential game-changer in the therapeutic landscape, and the clinical hold instigates concerns among stakeholders regarding the drug s viability and the overall trajectory of PepGen’s development pipeline. Adding to the complexity of this situation, PepGen’s financial performance tells a contrasting story. The company reported a year-on-year revenue decrease of 0% for the third quarter of 2024, a stark contrast to the 20.63% revenue growth experienced by many of its competitors in the biotechnology sector during the same period. This decline is alarming, particularly as the industry witnesses a general acceleration in income growth, with competitors reporting an astonishing average increase of 97.58%. The divergence between PepGen’s clinical and financial outcomes raises pressing questions about its business strategy and operational execution. While the biotechnology arena thrives on innovation and new therapeutic modalities, financial sustainability remains a critical pillar for long-term viability. The ongoing clinical hold could exacerbate investor concerns, potentially impacting public perception and market confidence in PepGen’s future prospects.





Financial Statements
Pepgen Inc's II. Quarter Investments $ 132 Millions PEPG's Balance sheet
Pepgen Inc's II. Quarter Income $ -18 Millions Quarterly PEPG's Income Statement
PEPG's Income by Division See PEPG's Income by Division


PEPG Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022
Total Investments in Millions 161 134 126 199 0
Y / Y Investment Growth 20.18 % 6.9 % -36.8 % - -
Net Income in Millions -90 -90 -79 -69 0
Y / Y Net Income Growth - - - - -
Annual Return On Investment -55.6 % -67.06 % -62.64 % -34.79 % -


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
PEPG's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for PEPG's Competitors
Subscribers only: Roi for Pepgen Inc's Suppliers
Subscribers only: Return On Investment for PEPG's Customers

Other Ratios
PEPG's Roa PEPG's Inventory Turnover Ratio PEPG's Growth Rates PEPG's Dividend Statistics
PEPG's Profitability Ratios PEPG's Asset Turnover Ratio PEPG's Dividend Growth
PEPG's Roe PEPG's Valuation Ratios PEPG's Financial Strength Ratios PEPG's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-09-26T07:41:43+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.